Skip to search formSkip to main contentSkip to account menu

SLV 306

Known as: SLV-306, SLV306 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Benzazepines
daglutril

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2014
Review
2014
Endothelin@25 – new agonists, antagonists, inhibitors and emerging research frontiers: IUPHAR Review 12
Since the discovery of endothelin (ET)‐1 in 1988, the main components of the signalling pathway have become established… 
2012
2012
The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans.
2004
2004
Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure.
2004
2004
Inhibition of Both Neutral Endopeptidase and Endothelin-Converting Enzyme by SLV306 Reduces Proteinuria and Urinary Albumin Excretion in Diabetic Rats
Diabetic nephropathy is a serious complication of diabetes associated with a poor prognosis which deteriorates to end-stage renal… 
Review
2003
Review
2003
SLV-306. Solvay.
  • Reza Tabrizchi
  • Current opinion in investigational drugs
  • 2003
  • Corpus ID: 19316501
SLV-306 is an orally active mixed neutral endopeptidase/endothelin converting enzyme inhibitor under development by Solvay SA for… 
2002
2002
SLV-306: Antihypertensive treatment of heart failure neprilysin inhibitor endothelin-converting enzyme inhibitor
Review
1992
Review
1992
Endothelin
In humans, the endothelins (ETs) comprise a family of three 21-amino-acid peptides, ET-1, ET-2 and ET-3. ET-1 is synthesised from… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)